§ 360g–2. Third party data transparency
331 words·~2 min read·
/usc/title-21/section-360g-2A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
To the extent the Secretary relies on any data, analysis, or other information or findings provided by entities that has been funded in whole or in part by, or otherwise performed under contract with, the Food and Drug Administration, in regulatory decision-making with respect to devices, the Secretary shall— request access to the datasets, inputs, clinical or other assumptions, methods, analytical code, results, and other components underlying or comprising the analysis, conclusions, or other findings upon which the Secretary seeks to rely; and in the event that information described in paragraph
(1)is used to support regulatory decision-making, and as otherwise appropriate, to the extent practicable, provide the manufacturer or manufacturers subject to such decision a summary of such information, subject to protection of confidential commercial information or trade secret information or personally identifiable information. Not later than September 30, 2023 , and biennially thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and publish on the website of the Food and Drug Administration, a report on the number of postmarket device signals communications issued by the Secretary, the sources of data for such signals, and how such signals were revised or resolved. Nothing in this section shall be construed to require the delay of any regulatory decision-making or other action of the Food and Drug Administration. ( Pub. L. 117–328, div. FF, title III, § 3307 , Dec. 29, 2022 , 136 Stat. 5834 .)
Connectionstraces to 1
Traces to 1 document
public-private-law
1 reference not yet in our index
- 136 Stat. 5834
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources